title: [Efficacy of tosufloxacin in genital chlamydial infections].
abstract: According to the 2006 and 2008 "Guidelines for diagnosis and treatment of sexually transmitted diseases" by the Japanese Society for Sexually Transmitted Diseases, quinolones, macrolides and tetracyclines are recommended to treat chlamydial infections. The administration method based on pharmacokinetic/pharmacodynamic theory, as well as the selection of antimicrobial drugs, is important in antimicrobial therapy. It is currently assumed that the efficacy of administering high-dose quinolones once a day is greater than dividing the dose over multiple administrations. To verify the treatment effects of the recommended tosufloxacin dose of 150 mg b.i.d. (300 mg/day) for 7 days, we performed a comparative multicenter open label study of 150 mg b.i.d. and 300 mg q.d. (300 mg/day). The results indicated complete efficacy with 100% (150 mg b.i.d.: 49/49, 300 mg q.d.: 57/57) eradication of Chlamydia trachomatis at both dosages. The clinical efficacy was "markedly effective" in 57.1% (28/49) of cases, "effective" in 42.9% (21/49), and "not effective" in 0% (0/49) in the 150 mg b.i.d. group, while these values were 59.6% (34/57), 40.4% (23/57) and 0% (0/57), respectively, in the 300 mg q.d. group. Quinolone therapy for genital chlamydial infections with tosufloxacin doses of 150 mg b.i.d. was confirmed to be effective as recommended in the guidelines. Moreover, tosufloxacin at 300 mg q.d. was shown to be an effective therapy.
authors.affiliation: Department of Infection Control Science, Graduate School of Medicine, Aichi Medical University School of Medicine.
authors.forename: Hiroshige
authors.initials: H
authors.lastname: Mikamo
authors.forename: Yuka
authors.initials: Y
authors.lastname: Yamagishi
authors.forename: Kaori
authors.initials: K
authors.lastname: Tanaka
authors.forename: Kunitomo
authors.initials: K
authors.lastname: Watanabe
authors.forename: Michihisa
authors.initials: M
authors.lastname: Fujiwara
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Iwasaku
authors.forename: Koji
authors.initials: K
authors.lastname: Izumi
authors.forename: Keiichi
authors.initials: K
authors.lastname: Takahashi
authors.forename: Ken
authors.initials: K
authors.lastname: Nakabe
authors.forename: Kenji
authors.initials: K
authors.lastname: Nozawa
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002690:Chlamydia Infections / Q000188:drug therapy*; D002692:Chlamydia trachomatis; D004334:Drug Administration Schedule; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage*; D005831:Genital Diseases, Female / Q000188:drug therapy*; D006801:Humans; D009287:Naphthyridines / Q000008:administration & dosage*; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; C055185:tosufloxacin